Key result
Caveolae-targeted Rem cuts pacing-induced NFAT nuclear translocation by ~90% while preserving myocyte contractility.
Why the study?
Does selective blockade of caveolae-localized L-type Ca2+ channels with Rem 1-265-Cav inhibit hypertrophic calcineurin-NFAT signaling without reducing cardiac myocyte contractility in adult feline left ventricular myocytes?
Does selective blockade of caveolae-localized L-type Ca2+ channels with Rem 1-265-Cav inhibit hypertrophic calcineurin-NFAT signaling without reducing cardiac myocyte contractility in adult feline left ventricular myocytes?
Provides proof-of-concept that Ca2+ influx through L-type Ca2+ channels within caveolin-3 signaling microdomains activates hypertrophic calcineurin-NFAT signaling and can be selectively blocked without impairing cardiac contractility.
Answers are grounded in this paper and cite their sources.
Supports selective caveolar LTCC inhibition to suppress NFAT signaling without impairing contractility; leaves open translation to human hypertrophy therapy.
RATIONALE: The source of Ca(2+) to activate pathological cardiac hypertrophy is not clearly defined. Ca(2+) influx through the L-type Ca(2+) channels (LTCCs) determines "contractile" Ca(2+), which is not thought to be the source of "hypertrophic" Ca(2+). However, some LTCCs are housed in caveolin-3 (Cav-3)-enriched signaling microdomains and are not directly involved in contraction. The function of these LTCCs is unknown. OBJECTIVE: To test the idea that LTCCs in Cav-3-containing signaling domains are a source of Ca(2+) to activate the calcineurin-nuclear factor of activated T-cell signaling cascade that promotes pathological hypertrophy. METHODS AND RESULTS: We developed reagents that targeted Ca(2+) channel-blocking Rem proteins to Cav-3-containing membranes, which house a small fraction of cardiac LTCCs. Blocking LTCCs within this Cav-3 membrane domain eliminated a small fraction of the LTCC current and almost all of the Ca(2+) influx-induced NFAT nuclear translocation, but it did not reduce myocyte contractility. CONCLUSIONS: We provide proof of concept that Ca(2+) influx through LTCCs within caveolae signaling domains can activate "hypertrophic" signaling, and this Ca(2+) influx can be selectively blocked without reducing cardiac contractility.
No takes yet. Share an insight, caveat, or question.
Makarewich et al. (2012) studied Pathological cardiac hypertrophy. Caveolae-targeted L-type Ca2+ channel antagonist (Rem 1-265-Cav) vs. Control uninfected myocytes, wild-type Rem (WT-Rem), and truncated Rem (Rem 1-265) was evaluated on Ca2+ influx-induced NFATc3-GFP nuclear translocation and myocyte fractional shortening. Caveolae-targeted Rem 1-265-Cav inhibited over 90% of pacing-induced NFAT nuclear translocation and ~15% of L-type Ca2+ current without reducing myocyte fractional shortening.
Synapse has enriched 10 related papers. Consider them for comparative context: